Sign in
Enrolling by invitationEarly phase 1

Portable Devices for Spotting Long-Term Illness Early in Clinics

Tests handheld ultrasound and blood sugar devices to find chronic diseases sooner.

Key facts

Who runs it
Truway Health, Inc.
Where
New York, United StatesSee the site
Trial code
Registry title
Truway Diagnostic Tools in Primary Care
Status
Enrolling by invitation
Phase
Early phase 1
People taking part
200 people, planned
Started
1 Oct 2025
Expected to end
1 Oct 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Truway Portable Ultrasound Device
  • Truway Blood Glucose Monitor
  • Standard Oral Hypoglycemic Agent
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with a chronic condition, such as diabetes, high blood pressure or kidney disease, who are on a stable treatment.

Age
18 to 75 years, inclusive
Sex
All sexes can join.
Disease stage
A diagnosed target condition, based on established clinical or diagnostic criteria. The listed conditions include type 2 diabetes, prediabetes, hypertension, high blood fats, chronic kidney disease stages 3-4 and peripheral artery disease.
Earlier treatment
A stable treatment plan for at least 4 weeks before screening.

Main reasons for not taking part

  • Pregnant or breastfeeding at enrollment
  • Known allergy to any part of the study intervention
  • Uncontrolled or unstable other health conditions (heart, liver, kidney or mental health)
  • Took part in another interventional trial in the past 3 months
  • Cognitive impairment or language barrier that prevents valid consent or reliable reporting

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age 18 to 75 years, inclusive
  • Ability to understand the study procedures and provide written informed consent
  • Diagnosis of the target condition according to established clinical or diagnostic criteria
  • Stable treatment regimen (pharmacologic or non-pharmacologic) for at least 4 weeks prior to screening
  • Willingness and ability to comply with all study visits, procedures, and follow-up assessments -

Who cannot take part

  • Known hypersensitivity to any components of the investigational intervention
  • Uncontrolled or unstable comorbid conditions (for example, cardiovascular, hepatic, renal, or psychiatric disorders)
  • Cognitive impairment or language barrier that would preclude valid informed consent or reliable reporting
  • Pregnancy or breastfeeding at the time of enrollment
  • Participation in another interventional clinical trial within the past 3 months
  • -

Where in United States

  • Truway Health, Inc.New York, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study evaluates the effectiveness of Truway Health-sourced portable diagnostic devices, including ultrasound and blood glucose monitors, in early detection of chronic conditions in outpatient primary care settings. Conducted as a prospective interventional trial, 200 participants will be assigned to use these devices versus standard care over a 6-month period. The primary outcome is improved diagnostic accuracy and patient outcomes. The study, led by Truway Health, Inc., aims to enhance accessible healthcare solutions starting at a New York site, with potential expansion to Miami.

The 2 groups in the trial

  • Intervention Group with Truway Diagnostic DevicesTreatment being tested

    Participants (n=100) will use Truway Health-sourced portable ultrasound and blood glucose monitors under supervised primary care protocols. The intervention aims to enhance early detection of chronic conditions (e.g., diabetes, cardiovascular disease) over 6 months, with follow-ups at 3 and 6 months to assess diagnostic accuracy and clinical outcomes. Devices are calibrated and provided by Truway Health, Inc., with training for care providers.

    Treatment: Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, and Standard Oral Hypoglycemic Agent

  • Control Group with Standard CareExisting treatment, for comparison

    Participants (n=100) will receive standard care without Truway diagnostic devices, following routine primary care practices for chronic condition management. Outcomes will be compared to the intervention group over 6 months, with follow-ups at 3 and 6 months to evaluate standard diagnostic accuracy and clinical results. No additional devices or training are provided.

    Treatment: Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, and Standard Oral Hypoglycemic Agent

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of Truway Health-Sourced Portable Diagnostic Devices for Early Detection of Chronic Conditions in Outpatient Primary Care Settings: A Prospective Interventional Study
Plain-language title
Portable Devices for Spotting Long-Term Illness Early in ClinicsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 November 2026